Table 2.
Dependent variables | Independent variables | B | P value | R2 total model |
---|---|---|---|---|
Fat malabsorption (total) | Genotype (WT = 0) | 2.5 | <0.001a | 0.53 |
Treatment (control = 0) | −0.38 | 0.47 | ||
Gender (female = 0) | 0.59 | 0.23 | ||
Fat malabsorption (saturated) | Genotype (WT = 0) | 7 | <0.001a | 0.6 |
Treatment (control = 0) | −1.8 | 0.16 | ||
Gender (female = 0) | 1.5 | 0.21 | ||
Fat malabsorption (unsaturated) | Genotype (WT = 0) | 0.77 | 0.001 | 0.33 |
Treatment (control = 0) | 0.17 | 0.47 | ||
Gender (female = 0) | 0.19 | 0.42 | ||
Fecal bile salt excretion (total) | Genotype (WT = 0) | 10.8 | <0.001a | 0.54 |
Treatment (control = 0) | −12.1 | <0.001a | ||
Gender (female = 0) | −5.7 | 0.06 | ||
Fecal bile salt excretion (primary) | Genotype (WT = 0) | 7.8 | <0.001a | 0.47 |
Treatment (control = 0) | −3.2 | 0.09 | ||
Gender (female = 0) | −0.6 | 0.7 | ||
Fecal bile salt excretion (secondary) | Genotype (WT = 0) | 1.4 | 0.4 | 0.38 |
Treatment (control = 0) | −6.2 | 0.003a | ||
Gender (female = 0) | −4.9 | 0.014a | ||
Body weight | Genotype (WT = 0) | −3.8 | <0.001a | 0.71 |
Treatment (control = 0) | −0.9 | 0.44 | ||
Gender (female = 0) | 0.8 | 0.51 | ||
Gender × treatment | 3.6 | 0.02a |
B, unstandardized β coefficient; CFTR, cystic fibrosis transmembrane conductance regulator; R2, regression correlation coefficient; WT, wild-type.
Statistically significant.